Human clinical trials scheduled
Scientists may have overcome a major roadblock in the development of Alzheimer’s therapies by creating a new technology to observe ? in the back of the eye ? progression of the disease before the onset of symptoms. Clinical trials are to start in July to test the technology in humans according to a paper recently published in Investigative Ophthalmology & Visual Science (IOVS).
The paper, titled Early detection of amyloidopathy in Alzheimer’s mice by hyperspectral endoscopy, builds upon previous work in cells by detecting changes in the retina of mice predisposed to develop Alzheimer’s.
Early detection of Alzheimer’s is critical for two reasons. “First, effective treatments need to be administered well before patients show actual neurological signs,” said author Robert Vince, PhD, of the Center for Drug Design at the University of Minnesota (UMN). “Second, since there are no available early detection techniques, drugs currently cannot be tested to determine if they are effective against early Alzheimer’s disease. An early diagnostic tool like ours could help the development of drugs as well.”
Looking through the eye to see the brain is a key advantage of the new technology. “The retina of the eye is not just ‘connected’ to the brain — it is part of the central nervous system,” said author Swati More, PhD, also of the Center for Drug Design at UMN. While the brain and retina undergo similar changes due to Alzheimer’s disease, “unlike the brain, the retina is easily accessible to us, making changes in the retina easier to observe.”
“We saw changes in the retinas of Alzheimer’s mice before the typical age at which neurological signs are observed,” said More. “The results are close to our best-case scenario for outcomes of this project.”
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Retired neurologist with Alzheimer’s knows firsthand the risks of Aduhelmon August 1, 2021 at 6:20 am
Neurologist Daniel Gibbs, diagnosed with Alzheimer’s disease in 2015, experienced some of the worst reported side effects of Aduhelm.
- Inspired by mother’s battle, woman rides for Alzheimer's researchon July 31, 2021 at 11:50 am
The month of July was a busy time in South Carolina for fundraising to help fight Alzheimer’s disease. Beginning on July 9, cyclists took a three-day, 252-mile ride from Simpsonville ...
- Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Diseaseon July 31, 2021 at 7:06 am
Simufilam Significantly Improves Cognition in Patients with Alzheimer’s in Interim Analysis of Open-label Study at 9 MonthsCognition Improved 3.0 Points on ADAS-Cog at 9 Months (p
- Will Biogen Be Able to Move Past the Drama Surrounding Its Alzheimer's Disease Drug?on July 31, 2021 at 4:03 am
Biogen's (NASDAQ: BIIB) history so far with Alzheimer's disease drug Aduhelm is like a biotech soap opera. In this Motley Fool Live video, recorded on July 19, 2021, healthcare and cannabis bureau ...
- Deaths from Alzheimer's disease far more common in rural U.S., study sayson July 30, 2021 at 10:05 pm
Death rates from Alzheimer's disease are particularly high in the rural United States, a preliminary study finds, highlighting a need for health care resources in traditionally under-served areas.
- Driving Patterns Pinpoint Early Alzheimer's Diseaseon July 30, 2021 at 1:31 pm
Driving behavior captured with a global positioning system (GPS) device discerned whether cognitively normal older drivers had preclinical Alzheimer's disease, an early stage when Alzheimer's ...
- Cassava Sciences Slides After Releasing Data On Its Alzheimer's Drugon July 30, 2021 at 7:54 am
Cassava Sciences, Inc. (SAVA) shares are sliding more than 14 percent on Friday morning trade, despite the company saying biomarker data with Simufilam in Alzheimer's disease is positive. There have ...
- Doctors Worry About COVID ‘Memory Problems’ And A Link To Alzheimer’s Diseaseon July 29, 2021 at 7:59 pm
There are two things that occupy much of my fears these days – COVID-19 and Alzheimer’s Disease. The former for obvious reasons. The latter because my dad has Alzheimer’s disease, which increases the ...
- Biogen, Eisai report design of real-world study of Alzheimer's treatmenton July 29, 2021 at 3:56 pm
Biogen Inc (BIIB.O) and partner Eisai Co Ltd (4523.T) on Thursday revealed the design of an upcoming study of their controversial Alzheimer's treatment, Aduhelm.
- Alzheimer’s disease signs seen in Covid patients suffering neurological symptomson July 29, 2021 at 12:44 pm
These new data point to disturbing trends, showing Covid-19 infections leading to lasting cognitive impairment and even Alzheimer’s symptoms,” said Heather M Snyder, Alzhei ...
via Bing News